Shocking Report Questions Efficacy of £90,000 Alzheimer’s Drugs
BBC Health
A shocking report reveals that breakthrough Alzheimer's drugs may not offer meaningful benefits, raising ethical concerns about patient care and costs.
New report claims breakthrough Alzheimer’s drugs may not help patients meaningfully.
Cochrane Collaboration's analysis suggests efficacy is overstated.
Patients face staggering costs of up to £90,000 for treatments.
Experts debate the validity and implications of the findings.